FOXO4-DRI
- Category
- Longevity & Anti-Aging
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A D-retro-inverso senolytic peptide that clears senescent cells by blocking the FOXO4-p53 interaction so p53 can trigger their self-destruction. Selective clearance has moderate support, but broader anti-aging claims rest on weak rodent and cell data with no human pharmacokinetics. The chief concern is that it manipulates p53, a key tumor suppressor, and human safety remains unknown. Supply is unregulated research-grade peptide, not an approved drug in the US.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
FOXO4-DRI is a synthetic peptide designed to selectively eliminate senescent cells — often called "zombie cells" — that accumulate with age and contribute to inflammation and tissue decline. In senescent cells, a protein called FOXO4 traps the tumor suppressor p53 in the nucleus, preventing the cell from self-destructing as it normally would. FOXO4-DRI works by displacing FOXO4, freeing p53 to trigger the cell's natural self-destruct program. It is a 46-amino-acid peptide with approximately 12-fold selectivity for senescent cells over healthy cells, developed at Erasmus University Medical Center Rotterdam by Peter de Keizer and colleagues.
How it works in the body
A D-retro-inverso peptide that disrupts the interaction between FOXO4 and p53 inside senescent cells. Normally, FOXO4 keeps p53 trapped in the nucleus of senescent cells, preventing their self-destruction. By blocking this interaction, FOXO4-DRI frees p53 to trigger apoptosis, selectively clearing senescent cells.
Research overview
FOXO4-DRI has been studied extensively in preclinical models since its landmark 2017 publication in Cell. In fast-aging mice, a 30-day treatment restored fur density, improved physical activity, and normalized kidney function. In naturally aged mice (about 2 years old), it similarly reduced markers of cellular senescence and improved kidney health. Additional studies have shown it can counteract chemotherapy-induced cell damage in the liver, restore testosterone levels in aged mice by clearing senescent cells in the testes, selectively remove senescent cells from human cartilage, improve blood vessel function, and reduce lung scarring (fibrosis). Second-generation versions (ES2 series) have been developed with 3-7 times greater potency. As of 2026, Cleara Biotech and Numeric Biotech are pursuing development of related compounds, but no human clinical trials have been initiated for FOXO4-DRI specifically. The compound remains preclinical.
Who researches FOXO4-DRI?
Commonly researched by
People exploring hormone and sexual health
Researched for effects on hormone levels, sexual function, or fertility.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
People researching kidney and renal health
Studied for renal protective or nephroprotective effects.
Important considerations for
Those with Active wound healing or surgery recovery
HighSenolytic action clears senescent cells needed for wound repair orchestration. May delay or impair healing.
Those who are pregnant or breastfeeding
AbsoluteInducing apoptosis of senescent cells during pregnancy could be extremely harmful to fetal development.
Those with Immune compromise
HighRapid clearance of senescent cells may overwhelm immune clearance capacity. Apoptotic debris can trigger secondary inflammation.
Those with Active cancer (p53-dependent tumors)
ModerateModulates p53 nuclear localization. Effects on p53-dependent tumor suppression are complex and unpredictable.
Safety & interactions
Do not use if
Active wound healing or surgery recovery
HighSenolytic action clears senescent cells needed for wound repair orchestration. May delay or impair healing.
Immune compromise
HighRapid clearance of senescent cells may overwhelm immune clearance capacity. Apoptotic debris can trigger secondary inflammation.
Active cancer (p53-dependent tumors)
ModerateModulates p53 nuclear localization. Effects on p53-dependent tumor suppression are complex and unpredictable.
General cautions
Pregnancy
AbsoluteInducing apoptosis of senescent cells during pregnancy could be extremely harmful to fetal development.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
All safety data from rodent studies and cell culture; no human pharmacokinetics
HighPMID 28340339 and all subsequent preclinical literature
Disrupts p53 dynamics; p53 is a critical tumor suppressor
ModerateMechanism — PMID 28340339; PMC8601985 (eBioMedicine 2021)
Human dosing extrapolated from mouse studies
ModeratePMID 28340339 (Cell 2017)
Injection site reactions
LowRoute/mechanism — PMID 28340339
Full spectrum of affected tissues not characterized
ModeratePreclinical literature to date
Unregulated products sold online; quality varies
HighRegulatory status (not FDA-approved)
Interaction summary(5)
Rated by direction with this peptide
Doxorubicin / anthracyclines and other senescence-inducing chemotherapy
ProtectiveModerateGiven after chemotherapy in mice, FOXO4-DRI cleared therapy-induced senescent cells and reduced doxorubicin chemotoxicity (restored body weight, lowered liver-damage markers) — a demonstrated protective effect against normal-tissue injury.
PMID 28340339 (Cell 2017)
Active malignancy / cancers with altered p53
CautionTheoreticalFOXO4-DRI transiently manipulates p53 regulation; its effect on tumor cells (especially p53-mutant cancers) is uncharacterized, so use during active cancer therapy is a mechanism-based concern, not a demonstrated harm.
Mechanism — PMID 28340339; PMC8601985
Navitoclax (ABT-263) / BCL-2-family senolytics
CautionTheoreticalUsing navitoclax with FOXO4-DRI adds navitoclax's on-target thrombocytopenia, a toxicity not seen with FOXO4-DRI in mouse experiments, to senolytic therapy; additive senescent-cell clearance is plausible but no safety data exist for the two together.
Mechanism / Baar comparison — PMID 28340339
Dasatinib + Quercetin, Fisetin (senolytic cocktails)
CautionTheoreticalOverlapping senolytic mechanisms could additively amplify senescent-cell clearance but also cumulative off-target toxicity; no human or animal combination studies have been performed.
Mechanism (senolytic class overlap)
Anticoagulants / antiplatelet agents
NeutralTheoreticalUnlike BCL-2-inhibitor senolytics, FOXO4-DRI did not reduce platelet counts in rodents, so no platelet-mediated bleeding interaction is expected — but this has not been confirmed in humans.
PMID 28340339 (Cell 2017)
Known risks(7)
No human safety data
HighAll safety data comes from rodent studies and cell culture. No systematic human pharmacokinetic, toxicology, or safety data exist.
Theoretical oncogenic concern
ModerateFOXO4-DRI disrupts p53 dynamics, and p53 is a critical tumor suppressor. While the peptide showed selectivity for senescent cells in preclinical studies, long-term effects on cancer risk are unknown.
Unknown dose-response in humans
ModerateHuman dosing is extrapolated from mouse studies. Optimal dosing, bioavailability, half-life, and tissue distribution in humans have not been characterized.
Potential injection site reactions
LowAs with all injectable peptides, redness, swelling, and pain at the injection site may occur.
Off-target effects not fully characterized
ModerateWhile selectivity was demonstrated in specific cell types, the full spectrum of tissues and cell types affected by FOXO4-DRI in a whole organism has not been comprehensively mapped.
Purity and quality variability
ModerateAs an unregulated research peptide, quality varies among unregulated products sold online. The 46-amino-acid D-retro-inverso synthesis is complex, and impurities or incorrect sequences are possible without pharmaceutical-grade manufacturing oversight.
Active cancer contraindication
HighUse in individuals with active cancer is contraindicated due to unknown effects on tumor-associated senescent cells and p53 pathway disruption in the tumor microenvironment.
Drug interactions(6)
Rapamycin (Sirolimus)
Rapamycin's mTOR inhibition may interfere with p53-mediated apoptotic signaling. A washout period of 1-2 weeks is suggested before FOXO4-DRI administration.
Quercetin
Quercetin has its own senolytic properties via different pathways. Concurrent use may diminish FOXO4-DRI efficacy. A minimum 96-hour washout period is suggested.
Corticosteroids / Cortisol
Anti-inflammatory corticosteroids may suppress the apoptotic signaling cascade triggered by FOXO4-DRI. Washout of 1-5 weeks recommended depending on corticosteroid type.
Dasatinib + Quercetin (D+Q)
D+Q targets BCL-2/BCL-XL pathways while FOXO4-DRI targets FOXO4-p53. These may be complementary when used sequentially rather than concurrently.
Fisetin
Fisetin has senolytic properties that may complement FOXO4-DRI through different mechanisms. Some protocols suggest combining them.
Doxorubicin / Chemotherapy agents
Preclinical data shows FOXO4-DRI can clear chemotherapy-induced senescent cells, potentially reducing long-term chemotoxicity. However, timing relative to chemotherapy must be carefully considered.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 12
- Human Studies
- 0
FOXO4-DRI has strong preclinical evidence from multiple independent labs across cell culture and animal studies, but no human clinical trials have been conducted. The original 2017 Cell paper demonstrated efficacy in three distinct mouse models (chemotoxicity, fast-aging, and natural aging). Subsequent studies have validated the approach in additional tissues including Leydig cells, chondrocytes, endothelial cells, and pulmonary fibroblasts. Second-generation variants with improved potency have been developed.
Researched for(8)
Rated by confidence in the evidence
Selective senescent cell clearance
MediumMultiple animal and cell studies show selective senescent-cell killing via a confirmed mechanism; no human trials.
PMID 28340339 (Cell 2017); PMC8116695; PMC7053614; PMC12852416
Restoration of kidney function in aging
LowOne 2017 mouse study restored kidney markers like creatinine clearance in naturally aged animals.
PMID 28340339 (Cell 2017)
Improved physical fitness and vitality in aged models
LowOne mouse study restored running capacity, coordination, and fur density across two aging models.
PMID 28340339 (Cell 2017)
Age-related testosterone restoration
LowIn aged mice, clearing senescent testicular cells eased age-related testosterone decline; single research group.
Aging 2020, doi:10.18632/aging.102682; PMC7053614
Chemotherapy-induced senescence mitigation
LowIn mice, dosing after doxorubicin reduced senescent-cell burden and eased chemotherapy toxicity; single study.
PMID 28340339 (Cell 2017)
Cartilage rejuvenation potential
SpeculativeLab-dish human cells lost senescent chondrocytes, but cartilage regeneration itself was not shown.
PMC8116695 (Front Bioeng Biotechnol 2021)
Vascular aging improvement
LowA single 2025 study in cells and mice reduced vascular aging markers and stiffness.
Front Bioeng Biotechnol 2025, doi:10.3389/fbioe.2025.1729166; PMC12852416
No platelet toxicity
LowPlatelet counts stayed normal in rodents, and it spares BCL-xL; no human data.
PMID 28340339 (Cell 2017)
Benefits(8)
Selective senescent cell clearance
11.7-fold selectivity for senescent vs. healthy cells demonstrated across multiple cell types (IMR90, WI-38, BJ fibroblasts) in Baar et al. 2017 (Cell)
Restoration of kidney function in aging
Normalized plasma urea and creatinine levels, restored LMNB1 expression in tubular cells in both fast-aging and naturally aged mice (Baar et al. 2017)
Improved physical fitness and vitality in aged models
Enhanced running wheel activity, fur density restoration, and improved responsiveness to stimuli in XpdTTD/TTD and naturally aged mice (Baar et al. 2017)
Age-related testosterone restoration
Significantly increased serum testosterone in 20-24 month old mice by clearing senescent Leydig cells and upregulating 3β-HSD and CYP11A1 enzymes (Zhang et al. 2020, Aging)
Chemotherapy-induced senescence mitigation
Counteracted doxorubicin-induced body weight loss, reduced liver damage (AST levels), and cleared chemotherapy-induced senescent cells (Baar et al. 2017)
Cartilage rejuvenation potential
Reduced senescence in expanded human chondrocytes from >40% to <5% at passage 9 while sparing early-passage cells (Huang et al. 2021, Frontiers in Bioengineering)
Vascular aging improvement
Suppressed aortic aging and improved aortic function in both naturally aged and induced aging mouse models (2025 vascular aging study)
No platelet toxicity
Unlike BCL-2 family inhibitors (ABT-263/navitoclax), FOXO4-DRI showed no thrombocytopenia after 30-day treatment in mice (Baar et al. 2017)
Key studies(6)
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Preclinical (in vivo + in vitro)Multiple mouse cohorts (p16::3MR transgenic, XpdTTD/TTD, naturally aged wild-type)30-day treatment protocolsBaar MP, Brandt RMC, Putavet DA, et al.
Cell
2017
FOXO4-DRI selectively induced apoptosis in senescent cells with 11.7-fold selectivity. In aged mice, restored kidney function, fur density, and physical activity. Counteracted doxorubicin chemotoxicity. No thrombocytopenia observed.
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
Preclinical (in vivo)20 aged mice (20-24 months), 10 young controls3 doses every other day, assessed at 30 daysZhang C, Xie Y, Chen H, et al.
Aging (Albany NY)
2020
FOXO4-DRI cleared senescent Leydig cells, restored testosterone synthesis enzyme expression (3β-HSD, CYP11A1), significantly increased serum testosterone, and reduced SASP factors (IL-1β, IL-6, TGF-β) in naturally aged mice.
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
In vitroHuman chondrocytes from 8 donors (ages 15-73)5-day treatment at 25 μMHuang J, He Y, Makarcyzk MJ, Lin H
Frontiers in Bioengineering and Biotechnology
2021
FOXO4-DRI reduced senescence in late-passage chondrocytes from >40% to <5% while having minimal impact on early-passage cells, demonstrating selective clearance of senescent cells in human tissue.
Development of a novel senolytic by precise disruption of FOXO4-p53 complex
Commentary/letterN/A — commentary on an experimental studyVariableTripathi U, Chaib S, Wissler Gerdes EO, et al.
eBioMedicine
2021
Commentary on ES2 peptide research by Le et al. (2021; PMID 34689087), with no new experiments.
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
Structural/MechanisticNMR structural analysisVarious authors
Nature Communications
2025
Revealed that disordered FOXO4-DRI binds to disordered p53TAD2, forming a transiently folded complex. Phosphorylation of p53 enhances affinity for both FOXO4 and FOXO4-DRI, explaining selectivity for senescent cells with activated p53.
Various authors
FEBS Letters
2018
Comprehensive review of the FOXO4-p53 signaling axis in cellular senescence, providing mechanistic context for FOXO4-DRI therapeutic development.
Regulation & availability
Why researchers look at it
The 2017 Cell paper showed that clearing senescent 'zombie cells' in aged mice restored fur density, improved kidney function, and increased physical activity in just 30 days. Multiple independent labs have since validated the approach across cartilage, blood vessels, testes, and lungs, with second-generation versions (ES2 series) showing 3-7x greater potency. Despite strong preclinical momentum and active pursuit by Cleara Biotech and Numeric Biotech, no human trials have started yet.
- FDA status
- FOXO4-DRI is not FDA-approved and is not eligible for compounding in the US. No published human clinical trial results were identified.
- WADA status
- FOXO4-DRI is not individually named. As an experimental pharmacological substance without identified approval for human therapeutic use, it falls under WADA's S0 non-approved-substance rule and is prohibited at all times. This classification applies the general rule rather than an individual WADA listing.
- Prescribability
- FOXO4-DRI is not FDA-approved and is not eligible for compounding in the US. No published human clinical trial results were identified.
- Availability
- FOXO4-DRI is not FDA-approved for human use and has no formal regulatory approval in any jurisdiction. Some longevity and anti-aging clinics in the United States offer FOXO4-DRI as an unapproved experimental drug under physician supervision. This is not ordinary off-label prescribing of an FDA-approved drug. Cleara Biotech (Netherlands) was formed to commercialize the FOXO4-p53 interaction disruption approach but remains in preclinical development as of 2026. Numeric Biotech has also become involved in development. The peptide is relatively expensive due to its 46-amino-acid length and D-retro-inverso synthesis requirements. CAS number: 2460055-10-9.
International status
EU
Not approved
US
Not FDA-approved
Worldwide
No regulatory approval in any jurisdiction
Regulatory timeline(6)
- 2017Landmark publication in Cell by Baar, de Keizer et al. at Erasmus University Medical Center demonstrating FOXO4-DRI efficacy in multiple mouse models
- 2017-2018Cleara Biotech founded in the Netherlands to commercialize FOXO4-p53 interaction disruption technology
- 2020Independent validation studies published (Leydig cell/testosterone restoration in aged mice by Zhang et al.)
- 2021Studies expand applications: chondrocyte senolytic clearance by Huang et al. and ES2 peptide development by Le et al.; Tripathi et al. published commentary on the latter work.
- 2025Nature Communications structural study reveals molecular mechanism of FOXO4-DRI binding to disordered p53TAD2 domain. Additional vascular aging studies published.
- 2026 (current)FOXO4-DRI remains an unapproved experimental compound, with no published human trial results identified. Human administration is not ordinary off-label use of an approved drug.
Sources & FAQs
Research sources(8)
- PubMed - Baar et al. 2017
- PMC - Original FOXO4-DRI study (Cell 2017)
- PubMed - Zhang et al. 2020 (Leydig cells)
- PubMed - Huang et al. 2021 (Chondrocytes)
- PubMed - Tripathi et al. 2021 (ES2 peptides)
- Nature Communications 2025 - Structural study
- Fight Aging! - 2026 development status
- PMC - FOXO4-p53 axis review
Frequently asked questions(6)
What is FOXO4-DRI and how does it work?
FOXO4-DRI is a D-retro-inverso peptide that selectively eliminates senescent ('zombie') cells. In senescent cells, the protein FOXO4 binds to p53 in the nucleus, preventing p53 from triggering cell death. FOXO4-DRI competes with FOXO4 for p53 binding, causing p53 to be expelled from the nucleus to the mitochondria, where it activates caspase-dependent apoptosis specifically in senescent cells.
What does 'D-retro-inverso' mean?
D-retro-inverso (DRI) refers to a peptide made from D-amino acids (mirror images of natural L-amino acids) with the sequence reversed. This makes the peptide resistant to protease degradation while maintaining similar binding properties to the original L-peptide, giving it a longer biological half-life.
Has FOXO4-DRI been tested in humans?
No formal human clinical trials have been completed as of 2026. All published evidence comes from cell culture (in vitro) and animal (in vivo) studies. Some individuals have used it through longevity clinics or self-experimentation, but systematic safety and efficacy data in humans do not exist.
How selective is FOXO4-DRI for senescent cells?
In the original 2017 Cell study, FOXO4-DRI showed approximately 11.7-fold selectivity for senescent cells over healthy cells. It specifically targets cells with active p53 signaling sequestered by FOXO4, which is characteristic of senescent cells but not normal cells.
Could FOXO4-DRI increase cancer risk by interfering with p53?
This is a theoretical concern. FOXO4-DRI disrupts FOXO4-p53 binding specifically in senescent cells where p53 is sequestered. In normal cells, p53 is not bound by FOXO4 in the same manner. The 2017 study showed no predisposition of healthy cells to DNA damage. However, long-term oncogenic risk has not been thoroughly evaluated, especially in humans.
How does FOXO4-DRI compare to other senolytics like dasatinib+quercetin?
FOXO4-DRI targets a different pathway (FOXO4-p53 interaction) compared to dasatinib+quercetin, which affect multiple kinase and cell-survival pathways. Mouse experiments did not show the platelet depletion associated with navitoclax; whether FOXO4-DRI has this safety advantage in humans is unknown. However, dasatinib+quercetin are small molecules with easier dosing and have been tested in human clinical trials.